A. List of external research funding Awarded as Principal Investigator in 2021-2022 2021-2022 年授予首席研究員的校外研究資助項目名單 Total HK$ 20,466,124.68 Research Grants Council Gernal Research Fund (2020/21) – Metformin as a neuroprotective therapy for glaucoma – A randomized controlled trial [Principal Investigator - Professor Christopher Leung] Health and Medical Research Fund (2020/21) – Applying virtual reality simulations to determine the development of vision – related disability in patients with glaucoma – A 3-year prospective study [Principal Investigator - Professor Christopher Leung] Arctic Vision Research Grant (2021) – Development of a microRNA–based ocular gene therapy for neuroprotection in glaucoma [Principal Investigator - Professor Christopher Leung] Glaucoma/Myopia OCT Phenotyping Consortium (GMPOC) (2021/22) – A multicenter study of myopic and/or glaucomatous optic nerve head, retinal nerve fiber layer and macula parameters measured with optical coherence tomography (OCT) [Hong Kong Principal Investigator - Professor Christopher Leung] Topcon Research Foundation (2021/22) – Application of wide-field optical coherence tomography imaging and trend-based progression analysis for detection of glaucoma of progression [Principal Investigator - Professor Christopher Leung] Health and Medical Research Fund (2020/21) – Preclinical evaluation of extra virgin olive oil and lutein-in-extra-virgin-olive-oil supplementation as a new avenue for prevention of retinopathy of prematurity [Principal Investigator - Dr Amy Lo] Health and Medical Research Fund (2020/21) – Randomized control trial on the efficacy of a smartphone application (Glaucomapp) on monitoring and promoting disease awareness and medication adherence on Chinese glaucoma patients [Principal Investigator - Dr Bonnie Choy] Alcon (2021) – CLOVE study: Clareon Intraocular lens stability in Vitrectomy patients [Principal Investigator - Dr Nicholas Fung] Roche Hong Kong Limited (2021) – Avonelle X: multicenter, Open-Label Extension Study to evaluate the long-term safety and tolerability of faricimab in patients with neovascular age-related macular degeneration [Principal Investigator - Dr Nicholas Fung] Roche Hong Kong Limited (2021) – Rhone X: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema [Principal Investor - Dr Nicholas Fung] Roche Hong Kong Limited (2021) – Balaton- A Phase III, Multicenter Randomized, Double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to branch retinal vein occlusion [Principal Investigator - Dr Nicholas Fung] Roche Hong Kong Limited (2021) – Comino-A Phase III, Multicenter Randomized, Double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to central retinal of hemiretinal vein occlusion [Principal Investigator - Dr Nicholas Fung] Amgen Hong Kong (2021) – A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration [Principal Investigator - Dr Nicholas Fung] 9 HKU Eye Center Inaugural Report The University of Hong Kong
RkJQdWJsaXNoZXIy Mzg4NDg0